Phenotypic screening in cancer drug discovery — past, present and future
The DOI matches its Crossref record; 181 of the 182 references it cites were found in a registry or an index.
Abstract
There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches. Given that oncology is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncology drug discovery by analysing the origins of all new small-molecule cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clinical development. Although the majority of these drugs originated from target-based discovery, we identified a significant number whose discovery depended on phenotypic screening approaches. We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes. However, technical and biological advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Phenotypic screening is a strategy that analyzes biology-associated (phenotypic) effects in given models such as animals, cells, or organisms to help identify the targets of candidate drugs.25,50”
From Drug repurposing for cancer therapy (2024) · cites this paper as [25]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Cited by
Items 301–400 of 523
Ontology-based validation and identification of regulatory phenotypes
Kulmanov, M., Schofield, P. N., Gkoutos, G. V., & Hoehndorf, R. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty605 · Cited by 9
Discovery of 2,4-dimethoxypyridines as novel autophagy inhibitors
Robke, L., Rodrigues, T., Schröder, P., Foley, D. J., Bernardes, G. J. L., Laraia, L., & Waldmann, H. (2018) · Tetrahedron · doi:10.1016/j.tet.2018.07.021 · Cited by 8
Wang, F., Prokeš, I., Song, L., Shi, H., & Sadler, P. J. (2022) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-022-01958-z · Cited by 8
“An alternative approach is phenotypic screening, which does not require much prior knowledge of a target, and often begins with cytotoxicity assays using cells in culture [2].”
BackgroundBioinformatics in Drug Discovery
Dao, N. A., Vu, T.-D., & Chu, D. (2024) · Springer eBooks · doi:10.1007/978-981-99-8401-5_11 · Cited by 14
Complex High-Content Phenotypic Screening
Horman, S. R. (2016) · InTech eBooks · doi:10.5772/65387 · Cited by 11
“Early phenotypic screening from the 1960s through the 1990s relied heavily on cytotoxic assays that identified anticancer drugs in human cell lines that exhibit the phenotype of rapid unrestrained growth [6].”
BackgroundYu, T., Zeng, R., Guan, Y., Pan, B., Li, H., Gu, J., Zheng, P., Yan, Q., & Ouyang, Q. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00136b · Cited by 8
Drug discovery and development: A historical overview, current challenges and perspectives
Yu, C. X., & Tham, C. L. (2024) · Life Sciences Medicine and Biomedicine · doi:10.28916/lsmb.8.1.2024.137 · Cited by 10
“…computational approaches in drug discovery and antiviral and antibacterial drug discovery, etc (Campbell et al., 2017; George et al., 2022; Henninot et al., 2018; Katz & Baltz, 2016; Moffat et al., 2014; Ong & Gasser, 2022; Pettersson & Crews, 2019; Totura & Bavari, 2019; Tse et al., 2019).”
Protein-protein complexes as targets for drug discovery against infectious diseases
Akhter, Y., & Hussain, R. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.11.012 · Cited by 10
Haak, A. J., Girtman, M. A., Ali, M. F., Carmona, E. M., LIMPER, A. H., & Tschumperlin, D. J. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.050 · Cited by 7
“The use of phenotype-based assays in drug discovery is continuing to expand, leading to the identification of promising drug candidates with no known mechanism of action or molecular target (Etzion and Muslin, 2009; Lee and Berg, 2013; Moffat et al., 2014).”
BackgroundSandrawati, N., Pariatno, R., Suharti, N., & Handayani, D. (2019) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2019.90809 · Cited by 7
“The research and development of anticancer drugs was the largest market area in the pharmaceutical industry and over 200 anticancer compound was in a various stage in a clinical trial (Moffat et al., 2014; Xu and Wenwei, 2016).”
BackgroundPhenotypic Drug Discovery: History, Evolution, Future
Swinney, D. C. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160721-00001 · Cited by 11
Li, Y., Qin, Z., Zhang, F., & Yang, S. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.28006 · Cited by 7
“Target‐based phenotypic drug discovery is an efficient strategy with simultaneous identification of new disease mechanisms used for the discovery of first‐in‐class drugs (Moffat et al., 2014; 2017; Swinney & Lee, 2020).”
MethodBioderived deep eutectic solvent-based topical chemotherapy for squamous cell carcinoma of the skin
Veríssimo, N. V. P., Toledo, D., Hakim, Q. A., Hill, A. R., Quintana, A. A., Escobar, C. R., Oluwole, S. A., & Agatemor, C. (2022) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2022.121029 · Cited by 7
Benham, V., Bullard, B. A., Dexheimer, T. S., Bernard, M. P., Neubig, R. R., Liby, K. T., & Bernard, J. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-46531-y · Cited by 7
Makino, T., Haruyama, M., Katayama, K., Terashima, H., Tsunemi, T., Miyazaki, K., Terakawa, M., Yamashiro, K., Yoshioka, R., & Maeda, H. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113717 · Cited by 8
Distance-Based Phylogenetic Methods
Xia, X. (2018) · Springer eBooks · doi:10.1007/978-3-319-90684-3_15 · Cited by 10
Empirical drug discovery: a view from the proteome
Lee, J. A., Carragher, N. O., & Berg, E. L. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.05.003 · Cited by 7
Affinity‐Based Chemoproteomics for Target Identification
Jensen, A. J., & Cornella‐Taracido, I. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527818242.ch2 · Cited by 8
He, S., & Lim, G. E. (2022) · Advanced Biology · doi:10.1002/adbi.202200151 · Cited by 8
Development of a phenotypic screening assay to measure activation of cancer-associated fibroblasts
Ilg, M. M., Lapthorn, A. R., Harding, S. L., Minhas, T., Koduri, G., Bustin, S. A., & Cellek, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1526495 · Cited by 6
Target-Based Screening for Lead Discovery
Kesh, M., & Goel, S. (2023) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-99-1316-9_7 · Cited by 7
Role of Bioinformatics in Drug Design and Discovery
Patel, P. H., JHA, A. N., & Chakraborthy, G. S. (2023) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-99-1316-9_1 · Cited by 7
Ji, W., Byun, W. S., Lu, W., Zhu, X., Donovan, K. A., Dwyer, B. G., Che, J., Yuan, L., Abulaiti, X., Corsello, S. M., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202308292 · Cited by 6
MicroRNA Therapeutics in Cardiovascular Disease
Bril, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_14 · Cited by 6
Preclinical Pharmacology and Toxicology - Contributions to the Translational Interface ☆
McGonigle, P., & Williams, M. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.05242-9 · Cited by 6
A new approach to assess drug sensitivity in cells for novel drug discovery
Mazzarella, L., & Curigliano, G. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1437136 · Cited by 6
“need to screen for biological phenotypes other than loss of cell viability [2]”
BackgroundXia, C., Sun, J., Wang, Q., Chen, J., Wang, T., Xu, W., Zhang, H., Li, Y., Chang, J., Shi, Z., et al. (2022) · Biosensors · doi:10.3390/bios12111048 · Cited by 6
Anti-Tumour Drugs: Planning Preclinical Efficacy and Safety Studies
Si, B., Pankratov, A. A., Nemtsova, E. R., Venediktova, Y. B., Vorontsova, M. S., Енгалычева, Г. Н., & Syubaev, R. D. (2020) · Ведомости Научного центра экспертизы средств медицинского применения · doi:10.30895/1991-2919-2020-10-2-96-110 · Cited by 9
“Фенотипический скрининг направлен на оценку цитотоксического действия лекарственных средств в отношении опухолевых клеток и считается полуэмпирическим подходом, который не требует знания основного механизма действия вещества [42].”
Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer
Pasqua, E., Wilding, B., Cheeseman, M. D., & Jones, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12395-9 · Cited by 6
Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2
Wang, M., Yang, S., Li, X., Zheng, Y., Bai, Y., Luo, W., Zhu, G., Chang, J., & Zhu, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01434 · Cited by 5
Alezi, D., Iskandrani, A., Ali, E. M. M., & Babgi, B. A. (2025) · Dalton Transactions · doi:10.1039/d5dt01851j · Cited by 6
Jadhav, V., Gurgude, R., & Sawant, R. (2025) · Next research. · doi:10.1016/j.nexres.2025.100986 · Cited by 6
Shukla, S., Trivedi, P., Johnson, D., Sharma, P., Jha, A., Khan, H., Thiruvenkatam, V., Banerjee, M., & Bishnoi, A. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d4cp02286f · Cited by 5
Tang, S., Sumitra, M. R., Kuo, Y.-C., Hsu, H.-L., Ansar, M., Huang, S., Lee, S., Wang, H.-J., Lawal, B., Wu, A. T. H., et al. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110445 · Cited by 6
Patient-Derived Conditionally Reprogrammed Cells in Prostate Cancer Research
Elbialy, A., Kappala, D., Desai, D. N., Wang, P., Fadiel, A., Wang, S.-J., Makary, M. S., Lenobel, S. S., Sood, A., Gong, M., et al. (2024) · Cells · doi:10.3390/cells13121005 · Cited by 7
“Particularly attractive are label-free in vitro phenotypic drug discovery assays [100–104] that do not require exogeneous probes, such as fluorescent dyes or reporter genes encoding a fluorescent protein [104,105] that can potentially interfere with target pharmacology [104].”
BackgroundJoignant, A. N., Pu, F., McLoughlin, S. M., Sawicki, J. W., Radosevich, A. J., Ma, R., Williams, J. D., Gopalakrishnan, S. M., & Elsen, N. L. (2025) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2025.100272 · Cited by 5
The Discovery Channel: microfluidics and microengineered systems in drug screening
Moraes, C. (2015) · Integrative Biology · doi:10.1039/c5ib90004b · Cited by 5
Quantitative Prioritization of Tool Compounds for Phenotypic Screening
Wang, Y., & Jenkins, J. L. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7847-2_15 · Cited by 5
Nucleotide Substitution Models and Evolutionary Distances
Xia, X. (2018) · Springer eBooks · doi:10.1007/978-3-319-90684-3_12 · Cited by 5
Cellular Imaging in Drug Discovery: Imaging and Informatics for Complex Cell Biology
Li, Z., Cvijic, M. E., & Zhang, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12328-5 · Cited by 5
Unwinding Fibrosis in Peyronie's Disease
Ilg, M. M., & Cellek, S. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.02.021 · Cited by 5
Schilf, P., Srinivasulu, V., Bolognesi, M. L., Ibrahim, S. M., Majdalawieh, A. F., Abu‐Yousef, I. A., Omar, H. A., El‐Awady, R., & Al‐Tel, T. H. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02669-3 · Cited by 5
Biswas, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.594750 · Cited by 6
“Thispotent research paradigm has been employed over the past few decades by the pharmaceutical and biotechnology sectors (Moffat et al., 2014, 2017).”
MethodPurification and Characterization of a Novel Fibrinolytic Enzyme from Cipangopaludina Cahayensis.
Zhao, T., Xiong, J., Chen, W., Xu, A., Zhu, D., & Liu, J. (2021) · PubMed Central · doi:10.30498/ijb.2021.2805 · Cited by 6
“Current anticancer therapeutics include alkylating agents, antimetabolites, antitumor antibiotics, plant antitumor drugs, hormones, metal platinum, auxiliary antitumor drugs, immunomodulators and mTOR inhibitors (5,6,7).”
BackgroundA Framework for Autonomous AI-Driven Drug DiscoveryPreprint
Selinger, D. W., Wall, T. R., Stylianou, E. S., Khalil, E. M., Gaetz, J., & Levy, O. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.17.629024 · Cited by 10
“However, identifying the molecular targets of the screening hits and the mechanisms involved, remains a difficult challenge ( 39 – 42 ) .”
Ilić, A., Zukic, S., Oljačić, S., Maran, U., Nikolic, K. M., & Popović-Nikolić, M. R. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020273 · Cited by 4
“In the search for combinations of compounds that exhibit synergistic effects, researchers can screen cell, tissue, and animal models [43].”
Evidence-based support for phenotypic drug discovery in acute myeloid leukemia
Vandersluis, S., Reid, J. C., Orlando, L., & Bhatia, M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103407 · Cited by 5
Herbst, K., Wang, T., Forchielli, E., Thommes, M., Paschalidis, I. C., & Segrè, D. (2024) · Communications Biology · doi:10.1038/s42003-024-06093-w · Cited by 4
“A particularly exciting potential application of MASS is in the selection of drug candidates for in vivo studies and ex vivo drug screening applications 64,65 .”
Bridging academic science and clinical research in the search for novel targeted anti-cancer agents.
Matter, A. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0079 · Cited by 5
Smart delivery of poly-peptide composite for effective cancer therapy
Yuan, X., Qin, Y., Tian, Q., Liu, C., Meng, X., Qie, B., Gao, F., Huang, Y., Xu, G., Yang, G., et al. (2022) · Biomedical Materials · doi:10.1088/1748-605x/ac494c · Cited by 4
Personalized Medicine in Oncology
Vanderwalde, A. M. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-2820-5 · Cited by 5
General Strategies for Rational Design and Discovery of Multitarget Drugs
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_18 · Cited by 6
Screening Microorganisms for Bioactive Compounds
Giubergia, S., Schleissner, C., de la Calle, F., Pretsch, A., Pretsch, D., Gram, L., & Thøgersen, M. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-33000-6_13 · Cited by 5
Tanabe, K., Inagaki, A., Henmi, Y., & Satake, M. (2018) · SLAS DISCOVERY · doi:10.1177/2472555217751091 · Cited by 5
“The cells were incubated with the following primary antibodies diluted with block buffer for 1 h at RT: anti-pERK (1:1000), anti-pAkt (1:2000), anti-PtdIns(4,5)P2”
MethodInfluentialDissecting phenotypic responses of the druggable targetome in cancers
Jeong, E., Park, C., Moon, S. U., Cho, J., Song, M., Ryoo, S., Gu, H., Lee, Y., Kim, W., & Yoon, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-48989-2 · Cited by 4
Medina, J. R., Tian, X., Li, W. H. C., Suarez, D., Mack, J. F., LaFrance, L. V., Martyr, C. D., Brackley, J. A., Marco, C. N. D., Rivero, R. A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01416 · Cited by 4
Strategies of Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_2 · Cited by 6
Non-Specificity of Drug-Target Interactions – Consequences for Drug Discovery
Maggiora, G. M., & Gokhale, V. M. (2016) · ACS symposium series · doi:10.1021/bk-2016-1222.ch007 · Cited by 5
Chemopreventive Potential of Flavones, Flavonols, and their Glycosides
Arroo, R., Wang, M. F., & Bhambra, A. S. (2020) · Springer eBooks · doi:10.1007/978-981-13-1745-3_5-1 · Cited by 4
Singh, L. R., Tripathi, V. C., Raj, S., Kumar, A., Gupta, S., Horam, S., Upadhyay, A., Kushwaha, P., Arockiaraj, J., Sashidhara, K. V., et al. (2018) · Drug Development Research · doi:10.1002/ddr.21458 · Cited by 4
García-Vázquez, N., Nada, H., Upadhyay, S., & Gabr, M. T. (2025) · RSC Advances · doi:10.1039/d5ra03914b · Cited by 3
Hendrickx, S., Ilbeigi, K., Thoré, E. S. J., Bertram, M. G., Calvo-Alvarez, E., Cintesun, S., Olías-Molero, A. I., Corral, M. A., Mateo, M., Estaquier, J., et al. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag110 · Cited by 3
Antibacterial drug discovery: challenges and preclinical promises from synthetic small molecules
Fernandes, G., Kim, S., dos Santos, J. L., Wang, Y., Soudy, C., Redmond, J. M., Castagnolo, D., & Todd, M. H. (2026) · Chemical Society Reviews · doi:10.1039/d5cs00617a · Cited by 5
Qureshi, M. H., Özlü, N., & Bayraktar, H. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106193 · Cited by 3
Elliott, R. J. R., Nagle, P. W., Furqan, M., Dawson, J. C., Smer-Barreto, V., Oyarzún, D. A., McCarthy, A., Munro, A. F., Drake, C., Morrison, G. M., et al. (2026) · iScience · doi:10.1016/j.isci.2026.115839 · Cited by 3
“27 The drug development of imidazotetrazines, such as temozolomide, extended from chemocentric and phenotypic-led collaborative research exploring the in vitro and in vivo anti-cancer properties of small molecules, dacarbazine and mitozolomide (azolastone), emphasizing the value of incorporating…”
Bioinformatics and Translation Initiation
Xia, X. (2018) · Springer eBooks · doi:10.1007/978-3-032-18842-7_10 · Cited by 4
Wray, J., & Whitmore, A. V. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_7 · Cited by 3
Sequential and Switchable Patterning for Studying Cellular Processes under Spatiotemporal Control
Zisis, T., Schwarz, J., Balles, M., Kretschmer, M., Némethová, M., Chait, R., Hauschild, R., Lange, J. R., Guet, C. C., Sixt, M., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c09850 · Cited by 3
A thiol-activated fluorogenic probe for detection of a target protein
Li, H., Lee, C., & Shin, I. (2022) · Chemical Communications · doi:10.1039/d2cc02029g · Cited by 3
Cellular imaging: a key phenotypic screening strategy for predictive toxicology
Xu, J. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00191 · Cited by 3
Protein Isoelectric Point and Helicobacter pylori
Xia, X. (2018) · Springer eBooks · doi:10.1007/978-3-032-18842-7_14 · Cited by 3
Preclinical Studies to Enable First in Human Clinical Trials
Chopra, R., & Raynaud, F. I. (2020) · Springer eBooks · doi:10.1007/978-3-030-47682-3_3 · Cited by 5
Swinney, D. C. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108175 · Cited by 3
Wang, L., Li, C., Chen, P., Liu, C., Cui, Z., Deng, S., & Yang, H. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00092 · Cited by 3
Segmentation of Heavily Clustered Cell Nuclei in Histopathological Images
Singh, R. K., Sharma, M., & Bhattacharya, M. (2017) · Lecture notes in computational vision and biomechanics · doi:10.1007/978-3-319-68195-5_27 · Cited by 3
Stefanovic, L., & Stefanovic, B. (2019) · Assay and Drug Development Technologies · doi:10.1089/adt.2018.904 · Cited by 3
“33,43,44 This prompts us to devise the phenotypic screen described here, as a technology to discover additional LARP6 inhibitors.”
Challenges and Options for Drug Discovery
Kramer, W. (2016) · Wiley eBooks · doi:10.1002/9783527693405.ch6 · Cited by 4
TOLEDO: Accelerated Maestro GUI molecular dynamics simulationsPreprint
Carmena‐Bargueño, M., Martínez-Cortés, C., Banegas‐Luna, A. J., & Pérez‐Sánchez, H. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-2qsc4-v2 · Cited by 3
FSL-CP: a benchmark for small molecule activity few-shot prediction using cell microscopy images
Ha, S. V., Leuschner, L., & Czodrowski, P. (2024) · Digital Discovery · doi:10.1039/d3dd00205e · Cited by 2
Recent advances in field effect transistor biosensors for drug screening applications
Chao, L., Liang, Y. J., & Hu, X. (2025) · The Analyst · doi:10.1039/d5an00206k · Cited by 2
Tong, L.-F., Ge, Y.-J., & Yang, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574540 · Cited by 4
“…(Luo et al., 2019; Chen et al., 2023) to experimentally synthesized small molecules (Rankin and Poulsen, 2017) and bioactive compounds screened by high-throughput screening (Mayoh et al., 2023; Khambhati et al., 2024) or cell-based phenotypic screening (Moffat et al., 2014; Selvin et al., 2023).”
Targeting the unexplored 'dark proteome': Novel approaches in drug discovery
Singh, D. (2025) · Current Proteomics · doi:10.1016/j.curpro.2025.100020 · Cited by 2
Drug repurposing in gynaecological cancers: Proven drugs for new challenges
Alghalayini, A., Sarker, F. A., Dickson, K.-A., Bowden, N. A., & Marsh, D. J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118885 · Cited by 2
Expanding the Connectivity Map Concept as the Functional Look-Up Table for Systems Biology
Lee, B. K. B., Cheong, S. C., & Tan, A. C. (2019) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2019.07.014 · Cited by 3
De, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13312-1.00006-4 · Cited by 2
Organic synthetic methodology-based new scaffolds in drug discovery
Ouyang, Q., Gu, J., & Zeng, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00025-5 · Cited by 3
TOLEDO: enhancing Maestro GUI for non-expert users to perform massive MD simulations
Carmena‐Bargueño, M., Martínez-Cortés, C., Banegas‐Luna, A. J., & Pérez‐Sánchez, H. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2423380 · Cited by 2
“This need is exemplified by the rise of antibiotic-resistant bacteria (Brown & Wright, 2016) or the ongoing quest for treatments for Parkinson’s (Van der Schyf, 2015), Alzheimer’s (Karran & Hardy, 2014), and Cancer (Moffat et al., 2014).”
Fleyshman, D. I., Cheney, P., Ströse, A., Mudambi, S., Safina, A. F., Commane, M., Purmal, A. A., Morgan, K. T., Wang, N. J., Gray, J. W., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1127478 · Cited by 2
A Review of Deep Genomics Applying Machine Learning in Genomic Medicine
Kim, T. H. (2017) · Hanyang Medical Reviews · doi:10.7599/hmr.2017.37.2.93 · Cited by 2
String Mathematics, BLAST, and FASTA
Xia, X. (2018) · Springer eBooks · doi:10.1007/978-3-319-90684-3_1 · Cited by 2
Kawamura, T., Futamura, Y., Shang, E., Muroi, M., Janning, P., Ueno, M., Wilke, J., Takeda, S., Kondoh, Y., Ziegler, S., et al. (2020) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2020.1812375 · Cited by 2
Yu, M., Li, C., He, M., Zhu, Y., Yang, R., Deng, S., Meng, X., & Yao, R. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02793-8 · Cited by 2
Akpe, V., Murhekar, S., Kim, T. H., Brown, C. L., & Cock, I. E. (2021) · Assay and Drug Development Technologies · doi:10.1089/adt.2020.1016 · Cited by 2
Chemopreventive Potential of Flavones, Flavonols, and their Glycosides
Arroo, R., Wang, M. F., & Bhambra, A. S. (2021) · Springer eBooks · doi:10.1007/978-981-15-4148-3_5 · Cited by 2
Computational Approaches for Target Inference
Heßler, G., Grebner, C., & Matter, H. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527818242.ch10 · Cited by 2
Xia, X. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00023-7 · Cited by 1
Development of the basics of production technology of dacarbazine substance with anticancer effect
Stasevych, M., Kusyi, М. А., & Mickevičius, V. (2024) · Chemistry Technology and Application of Substances · doi:10.23939/ctas2024.02.107 · Cited by 1
Experimental Assays: Chemical Properties, Biochemical and Cellular Assays,and In Vivo Evaluations
Serafim, M. S. M., Reis, E. V. D. S., Coelho-dos-Reis, J. G. A., Abrahão, J. S., & O’Donoghue, A. J. (2024) · Computer-aided drug discovery and design · doi:10.1007/978-3-031-76718-0_12 · Cited by 2
Hydrophilic/Omniphobic Droplet Arrays for High-throughput and Quantitative Enzymology
Lee, B., Sunden, F., Miller, M. S., Pak, B., Krebber, A., Lutz, S., & Fordyce, P. M. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c00333 · Cited by 3
Metadata
- Authors
- Moffat, J. G., Rudolph, J., & Bailey, D.
- Affiliations
- Genentech (US)
- Corresponding author
- Moffat, John G.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-07-18
- Volume
- 13
- Issue
- 8
- Pages
- 588-602
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2123059506
- Semantic Scholar
- 1042a4c884176fac046b7c6751c953ed949f8066
- Cited by
- 507
- References
- 182
- Citations by year
- 2026: 28 · 2025: 37 · 2024: 43 · 2023: 30 · 2022: 36 · 2021: 48 · 2020: 45 · 2019: 48 · 2018: 52 · 2017: 56 · 2016: 42 · 2015: 39 · 2014: 3
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Food and Drug Administration
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- phenotypic screening, anticancer drug discovery, anticancer drug development, small molecule anticancer agents, FDA-approved anticancer drugs, target-based drug discovery, cytotoxicity, mitotic arrest
- MeSH terms
- Antineoplastic Agents, Drug Screening Assays, Antitumor, Forecasting, Humans, Neoplasms, Phenotype, History, 20th Century, History, 21st Century, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.